Skip to main content

Volume 16 Supplement 1

1st Joint ANIRCEF-SISC Congress

Choosing the safest acute combination therapy during prophylactic treatment: pharmacokinetic and pharmacodynamic considerations

Drugs used in the treatment of migraine have been recently reported to be highly associated with the occurrence of clinically significant drug-drug interactions (DDIs). The multiple drug therapy regimen is widely used for migraine treatment, particularly for chronic migraine. In fact, additional pharmacological agents are usually administered during an acute migraine attack in patient chronically treated with prophylactic therapy. The wide variety of drugs available for migraine prophylactic and acute treatment, and consequently their pharmacological interactions, might complicate the choice of a safe combination therapy. The most frequently used drugs for the prophylactic therapy of migraine belong to the antiepileptic, β-blockers, tricyclic, SSRIs and SNRIs antidepressants and antihistamine medications while acute migraine attacks are treated with triptans, NSAIDs and ergot derivatives. Moreover, in the last few years several of the latter drugs have been combined in new formulations for clinical use in order to improve treatment efficacy and, consequently, the compliance of the patient. Drug-drug interactions might occur at receptors level, both in the Central Nervous System (CNS) and in the periphery, at the major metabolic pathways levels (i.e., CYP450 enzymes) and at the protein binding level. One of the most widely known examples of the severity of such interactions is represented by the serotoninergic syndrome induced by the co-administration of serotoninergic antidepressants and triptans.

In the management of chronic migraine, usually prophylactic treatment is already administered, therefore the choice of an additional drug for the acute attack should be decided considering the specific DDIs.

Therefore, the aim of this study was to schematically discuss the prophylactic-acute drug-drug interactions from a pharmacokinetic and pharmacodynamic point of view.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Luana Lionetto.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lionetto, L., Martelletti, P. Choosing the safest acute combination therapy during prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. J Headache Pain 16, A36 (2015). https://doi.org/10.1186/1129-2377-16-S1-A36

Download citation

Keywords

  • Migraine
  • Chronic Migraine
  • Prophylactic Treatment
  • Prophylactic Therapy
  • Major Metabolic Pathway